-
2024-514799-42-00
4
2024-11-05
IDIOPATHIC PULMONARY FIBROSIS
-
2023-508805-26-00
1
2024-10-23
patients with active brain metastases, where the primary tumour has co
-
2023-505486-92-00
4
2024-02-09
Small bowel adenocarcinoma
-
2022-501703-27-00
5
2023-07-05
Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia
-
2023-506548-18-00
10
2022-11-10
Dermatitis atopic
-
2024-519620-24-01
5
2026-06-01
ANCA-associated vasculitis
-
2023-505046-26-00
5
2026-05-07
Colon carcinoma
-
2023-509891-40-00
5
2026-04-28
Pulmonary arterial hypertension
-
2024-519208-29-00
4
2026-04-02
Pleural mesothelioma
-
2025-522108-26-00
4
2026-02-19
métastatique colorectal cancer
-
2025-521873-15-00
9
2026-02-09
Metastatic hormone-sensitive prostate cancer
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2024-515948-23-00
5
2026-02-06
Advanced pulmonary or gastroenteropancreatic poorly differentiated neu
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2025-521606-18-00
4
2026-01-29
Ovarian Cancer
-
2025-522333-61-00
4
2026-01-23
Hidradenitis suppurativa
-
2024-515023-11-00
5
2026-01-22
Metastatic Clear Cell Renal Cell Carcinoma
-
2024-518385-26-01
5
2025-12-18
Polymyalgia Rheumatica (PMR)
-
2025-521128-31-00
9
2025-12-18
Locally Advanced or Metastatic Estrogen Receptor-Positive, human epide
-
2024-516789-13-00
6
2025-12-15
Severe asthma
-
2025-522395-92-00
5
2025-12-15
metastatic oeso-gastric adenocarcinoma
-
2024-519345-30-00
5
2025-11-12
IgA nephropathy